Detect, through a blood test, a risk of relapse in order to administer preventive treatment; evaluate the effectiveness of different chemotherapies on tumor replicas to identify the best therapeutic option; or even further personalize treatments: so many advances presented at the annual congress of Asco (American Society of Clinical Oncology), an unmissable event in cancer research, which was held from May 29 to June 2. La Croix has selected some of this good news, resulting from work carried out by France.
This article is reserved for subscribers
Would you like to read more? Subscribe without obligation to our digital offer
I subscribe
